HCV resistance and treatment failure

HCV & DAAs - The Antiviral Arsenal

Direct-Acting Antivirals (DAAs) target specific HCV non-structural proteins to halt viral replication. Key classes include:

• NS3/4A Protease Inhibitors (-previr): E.g., Glecaprevir. Block post-translational processing of the HCV polyprotein.
• NS5A Inhibitors (-asvir): E.g., Pibrentasvir. Interfere with viral replication and assembly.
• NS5B Polymerase Inhibitors (-buvir): E.g., Sofosbuvir. Inhibit the RNA-dependent RNA polymerase, terminating chain elongation.

📌 Previr = Protease | Asvir = NS5A | Buvir = NS5B.

⭐ Sofosbuvir, a nucleotide analog NS5B inhibitor, has a high genetic barrier to resistance, making it a cornerstone of many DAA regimens.

Mechanisms of Resistance - Viral Escape Tactics

• Genetic Plasticity: HCV's high replication rate (≈$10^{12}$ virions/day) and error-prone RNA polymerase (NS5B) create a diverse viral "quasispecies," ripe for mutations.
• Resistance-Associated Variants (RAVs): These are mutations in DAA target regions (NS3/4A, NS5A, NS5B) that reduce drug susceptibility.
  • Pre-existing: Naturally present at low levels before therapy begins.
  • Emergent: Selected for and become dominant under the pressure of DAA treatment, leading to virologic failure.

⭐ NS5A RAVs: Mutations in the NS5A region (e.g., Y93H) are a major cause of treatment failure for many DAA regimens. They can confer high-level resistance and persist for years after treatment cessation.

Clinically Significant RAVs - The Usual Suspects

• NS5A Inhibitors (-asvirs): Low Barrier to Resistance

  • Most common site for clinically significant RAVs. Single amino acid changes can confer high-level resistance.
  • Key RAVs include Q30R, L31M/V, and Y93H/N.
  • These variants primarily impact the "-asvir" class (e.g., Ledipasvir, Daclatasvir).

• NS5B Polymerase Inhibitors (-buvirs): High Barrier to Resistance

  • Sofosbuvir is robust against resistance; clinically significant RAVs are rare.
  • The key (but unfit and rare) mutation is S282T.

⭐ Pre-treatment RAV testing (especially for NS5A variants) is crucial in specific scenarios, such as prior DAA failure or when considering certain regimens like Elbasvir/Grazoprevir for HCV genotype 1a.

Managing Treatment Failure - Salvage & Strategy

• Post-Failure Workup: Test for Resistance-Associated Variants (RAVs), especially in the NS5A gene, to guide subsequent therapy selection.
• Salvage Principles:
  • Switch to different DAA classes not previously used.
  • Use potent, pangenotypic regimens.
  • Consider extending treatment duration (e.g., 12-16 weeks) or adding Ribavirin (RBV), especially with cirrhosis or complex RAVs.

⭐ Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) is a highly effective single-tablet salvage regimen for patients who have failed prior DAA therapy, including those with NS5A RAVs.

High‑Yield Points - ⚡ Biggest Takeaways

• HCV's high mutation rate, via its error-prone RNA polymerase (RdRp), is the primary driver of resistance.
• Resistance-Associated Substitutions (RASs) can emerge during therapy, leading to treatment failure.
• NS5A inhibitor resistance is common and clinically significant, sometimes requiring baseline RAS testing.
• Mutations in NS5B polymerase and NS3/4A protease also confer resistance to their respective DAAs.
• Treatment failure requires switching to a DAA regimen with a different mechanism of action.
• Salvage therapy may involve combining DAAs, often with ribavirin.